AP2015008233A0 - Novel rebamipide prodrugs, preparation method and use thereof - Google Patents

Novel rebamipide prodrugs, preparation method and use thereof

Info

Publication number
AP2015008233A0
AP2015008233A0 AP2015008233A AP2015008233A AP2015008233A0 AP 2015008233 A0 AP2015008233 A0 AP 2015008233A0 AP 2015008233 A AP2015008233 A AP 2015008233A AP 2015008233 A AP2015008233 A AP 2015008233A AP 2015008233 A0 AP2015008233 A0 AP 2015008233A0
Authority
AP
ARIPO
Prior art keywords
preparation
novel rebamipide
rebamipide prodrugs
prodrugs
novel
Prior art date
Application number
AP2015008233A
Other languages
English (en)
Inventor
Sung Ju Choi
Hyun Tae Kim
Jae Woong Lee
Original Assignee
Astech Co Ltd
Samjin Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49783488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008233(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astech Co Ltd, Samjin Pharm Co Ltd filed Critical Astech Co Ltd
Publication of AP2015008233A0 publication Critical patent/AP2015008233A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2015008233A 2012-06-26 2013-06-26 Novel rebamipide prodrugs, preparation method and use thereof AP2015008233A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120068394 2012-06-26
PCT/KR2013/005622 WO2014003424A1 (fr) 2012-06-26 2013-06-26 Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation

Publications (1)

Publication Number Publication Date
AP2015008233A0 true AP2015008233A0 (en) 2015-01-31

Family

ID=49783488

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008233A AP2015008233A0 (en) 2012-06-26 2013-06-26 Novel rebamipide prodrugs, preparation method and use thereof

Country Status (27)

Country Link
US (1) US11420963B2 (fr)
EP (1) EP2865669B1 (fr)
JP (1) JP6032451B2 (fr)
KR (1) KR101452277B1 (fr)
CN (1) CN104662004B (fr)
AP (1) AP2015008233A0 (fr)
AR (1) AR097226A1 (fr)
AU (1) AU2013281442B2 (fr)
BR (1) BR112014032627A8 (fr)
CA (1) CA2877853C (fr)
CL (1) CL2014003496A1 (fr)
CO (1) CO7240352A2 (fr)
ES (1) ES2875863T3 (fr)
IL (1) IL236479A0 (fr)
MA (1) MA37676B1 (fr)
MX (1) MX2015000023A (fr)
NZ (1) NZ704023A (fr)
PE (2) PE20160285A1 (fr)
PH (1) PH12015500172B1 (fr)
RU (1) RU2612509C2 (fr)
SA (1) SA113340675B1 (fr)
SG (1) SG11201408711PA (fr)
TW (1) TWI483727B (fr)
UA (1) UA113990C2 (fr)
UY (1) UY34882A (fr)
WO (1) WO2014003424A1 (fr)
ZA (1) ZA201500450B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
WO2016108319A1 (fr) * 2015-01-02 2016-07-07 삼진제약 주식회사 Nouveau sel de promédicament du rébamipide et son utilisation
KR20170094584A (ko) * 2016-02-11 2017-08-21 삼진제약주식회사 레바미피드 전구체를 포함하는 면역질환 및 대사성질환의 예방 또는 치료를 위한 경구투여용 약제학적 조성물
KR102190019B1 (ko) * 2018-10-23 2020-12-15 삼진제약주식회사 쇼그렌 증후군 예방 또는 치료용 조성물
PL3797771T3 (pl) * 2019-09-03 2022-06-27 Square Power Ltd Rebamipid do stosowania w zapobieganiu i leczeniu celiakii
EP3797773A1 (fr) * 2019-09-03 2021-03-31 Square Power Ltd Rebamipide destiné à être utilisé dans la prévention et le traitement du cancer
CN111595985B (zh) * 2020-07-09 2022-03-29 苏州正济药业有限公司 一种用hplc测定瑞巴派特有关物质的分析方法
WO2024224086A1 (fr) 2023-04-27 2024-10-31 Imhotex Limited Diacides de desmuramylpeptides en tant qu'agonistes de nod2 et leur utilisation
WO2024224093A1 (fr) 2023-04-27 2024-10-31 Imhotex Limited Diesters de desmuramylpeptides en tant qu'agonistes de nod2 et leur utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578381A (en) 1982-07-05 1986-03-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JPS6019767A (ja) * 1983-07-11 1985-01-31 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体を有効成分とする抗潰瘍剤
JP3621463B2 (ja) * 1995-04-26 2005-02-16 大塚製薬株式会社 カルボスチリル誘導体ビスマス塩
KR100669823B1 (ko) * 2001-02-20 2007-01-17 경동제약 주식회사 2-(4-클로로벤조일아미노)-3-[2(1h)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체
EP1336602A1 (fr) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Prodrogues nitrées capable de libérer du monoxyde d'azote de manière controlée et sélective ainsi que leur utilisation pour la prévention et le traitement de maladies inflammatoires, ischémiques et proliferatives
KR20040104020A (ko) 2003-06-02 2004-12-10 진양제약주식회사 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제
TWI363626B (en) * 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
US7718805B2 (en) * 2004-12-01 2010-05-18 Otsuka Pharmaceutical Co., Ltd. Process for preparing rebamipide
JP2008105970A (ja) * 2006-10-24 2008-05-08 Ohara Yakuhin Kogyo Kk ジヒドロキノリン誘導体の製造方法及びその中間体
WO2008074853A1 (fr) 2006-12-21 2008-06-26 Novartis Ag Solution ophtalmique de rebamipide
KR101032600B1 (ko) 2008-08-11 2011-05-06 동우신테크 주식회사 고순도 레바미피드의 제조방법
KR101182114B1 (ko) 2010-03-05 2012-09-12 한림제약(주) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
CN102174015B (zh) * 2011-03-07 2013-10-16 江西同和药业有限责任公司 瑞巴派特的精制方法

Also Published As

Publication number Publication date
BR112014032627A8 (pt) 2021-08-31
PH12015500172A1 (en) 2015-03-16
CA2877853A1 (fr) 2014-01-03
SG11201408711PA (en) 2015-01-29
AU2013281442B2 (en) 2016-09-15
MA37676A1 (fr) 2016-10-31
KR20140001767A (ko) 2014-01-07
US20150141409A1 (en) 2015-05-21
TW201402118A (zh) 2014-01-16
ES2875863T3 (es) 2021-11-11
TWI483727B (zh) 2015-05-11
CL2014003496A1 (es) 2015-08-07
PE20150904A1 (es) 2015-06-13
PE20160285A1 (es) 2016-04-27
CN104662004B (zh) 2017-04-19
RU2612509C2 (ru) 2017-03-09
IL236479A0 (en) 2015-02-26
RU2015102043A (ru) 2016-08-10
WO2014003424A1 (fr) 2014-01-03
NZ704023A (en) 2016-03-31
CO7240352A2 (es) 2015-04-17
MX2015000023A (es) 2015-10-05
EP2865669A4 (fr) 2015-12-02
KR101452277B1 (ko) 2014-10-24
BR112014032627A2 (pt) 2017-06-27
AU2013281442A1 (en) 2015-02-12
SA113340675B1 (ar) 2015-08-16
EP2865669A1 (fr) 2015-04-29
PH12015500172B1 (en) 2015-03-16
JP6032451B2 (ja) 2016-11-30
EP2865669B1 (fr) 2021-04-28
ZA201500450B (en) 2016-05-25
CA2877853C (fr) 2018-01-02
MA37676B1 (fr) 2017-07-31
UY34882A (es) 2014-01-31
JP2015522585A (ja) 2015-08-06
UA113990C2 (xx) 2017-04-10
AR097226A1 (es) 2016-03-02
US11420963B2 (en) 2022-08-23
CN104662004A (zh) 2015-05-27

Similar Documents

Publication Publication Date Title
DK2922554T3 (en) Terminalt modificeret rna
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
IL235512A0 (en) New methods
GB201217018D0 (en) Methods
ZA201500450B (en) Novel rebamipide prodrugs, preparation method and use thereof
GB201216800D0 (en) Novel use
SG11201501689RA (en) Toughening masterblends
GB2502767B (en) Cannula
GB201208874D0 (en) Methods
GB2507760B (en) Methods
SG11201408326TA (en) Preparation method for perfluoro-2-methyl-3-pentanone and intermediate
ZA201500692B (en) Benzodioxole derivative and preparation method and use thereof
EP2805954A4 (fr) Dérivé d'hanfangichin b substitué en position 7, et procédé de préparation et utilisation de celui-ci
GB201223330D0 (en) Products, methods and uses
GB2503737B (en) Carabiner
GB201213778D0 (en) Process and dressng
GB201204280D0 (en) Methods
PT2895176T (pt) Intermediário de rivaroxabano e a sua preparação
PL2908859T3 (pl) Formulacje arypiprazolu
EP2870133A4 (fr) Dérivés tétrahydro-isohumulone et procédés de fabrication et d'utilisation associés
GB201209689D0 (en) Methods
PL398018A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PL398021A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
GB201220686D0 (en) Methods
GB201208963D0 (en) Methods